DOP2023000253A - Compuestos y métodos dirigidos a la epirregulina - Google Patents

Compuestos y métodos dirigidos a la epirregulina

Info

Publication number
DOP2023000253A
DOP2023000253A DO2023000253A DO2023000253A DOP2023000253A DO P2023000253 A DOP2023000253 A DO P2023000253A DO 2023000253 A DO2023000253 A DO 2023000253A DO 2023000253 A DO2023000253 A DO 2023000253A DO P2023000253 A DOP2023000253 A DO P2023000253A
Authority
DO
Dominican Republic
Prior art keywords
chronic
epirregulin
compounds
pain
methods directed
Prior art date
Application number
DO2023000253A
Other languages
English (en)
Inventor
Parvin Johnson Michael
Streetman Boyles Jeffrey
Brautigam Beidler Catherine
Scott Girard Daniel
Marie Harlan Shannon
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2023000253A publication Critical patent/DOP2023000253A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con anticuerpos de la epirregulina, composiciones que los comprenden, y métodos para elaborar y/o usar los anticuerpos y/o composiciones de estos para trastornos del dolor crónico tales como el dolor de la osteoartritis crónico, o el dolor de la neuropatía periférica diabética crónico, o el dolor lumbar crónico
DO2023000253A 2021-05-21 2023-11-16 Compuestos y métodos dirigidos a la epirregulina DOP2023000253A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163191496P 2021-05-21 2021-05-21
PCT/US2022/030058 WO2022246078A1 (en) 2021-05-21 2022-05-19 Compounds and methods targeting epiregulin

Publications (1)

Publication Number Publication Date
DOP2023000253A true DOP2023000253A (es) 2023-12-29

Family

ID=82100776

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2023000253A DOP2023000253A (es) 2021-05-21 2023-11-16 Compuestos y métodos dirigidos a la epirregulina

Country Status (16)

Country Link
US (1) US20220372124A1 (es)
EP (1) EP4341288A1 (es)
KR (1) KR20240009488A (es)
CN (1) CN117440968A (es)
AR (1) AR125902A1 (es)
AU (1) AU2022277694A1 (es)
BR (1) BR112023021829A2 (es)
CA (1) CA3218753A1 (es)
CO (1) CO2023015694A2 (es)
CR (1) CR20230538A (es)
DO (1) DOP2023000253A (es)
EC (1) ECSP23087684A (es)
IL (1) IL308533A (es)
PE (1) PE20240416A1 (es)
TW (1) TW202313680A (es)
WO (1) WO2022246078A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4969440B2 (ja) * 2004-04-08 2012-07-04 デビッド， ビー． エイガス， 疼痛治療のためのＥｒｂＢアンタゴニスト
AR085484A1 (es) 2011-04-06 2013-10-02 Lilly Co Eli ANTICUERPOS QUE SE UNEN A TGF-a Y EPIREGULINA
MX2015007719A (es) * 2012-12-21 2015-09-07 Sykehuset Sørlandet Hf Terapia dirigida del receptor del factor de crecimiento epidermico (egfr) de trastornos neurologicos y dolor.

Also Published As

Publication number Publication date
IL308533A (en) 2024-01-01
AU2022277694A9 (en) 2023-12-07
CN117440968A (zh) 2024-01-23
TW202313680A (zh) 2023-04-01
AR125902A1 (es) 2023-08-23
CA3218753A1 (en) 2022-11-24
WO2022246078A1 (en) 2022-11-24
CO2023015694A2 (es) 2023-11-30
AU2022277694A1 (en) 2023-11-30
EP4341288A1 (en) 2024-03-27
BR112023021829A2 (pt) 2023-12-19
KR20240009488A (ko) 2024-01-22
PE20240416A1 (es) 2024-03-05
US20220372124A1 (en) 2022-11-24
ECSP23087684A (es) 2023-12-29
CR20230538A (es) 2023-12-11

Similar Documents

Publication Publication Date Title
BR112022009679A2 (pt) Receptores de antígeno quimérico cd19 e cd22 e usos dos mesmos
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
CO2020010465A2 (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
UY36302A (es) Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
GT201200258A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
UY38003A (es) Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas
CO2017011958A2 (es) Benzamidas sustituidas y métodos para utilizarlas
CO2021004560A2 (es) Anticuerpos estabilizadores de trem2
CO2019012767A2 (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
CL2018003377A1 (es) Compuestos novedosos para tratar enfermedades parasitarias. (divisional solicitud 201803187)
AR105778A1 (es) Composiciones de materia grasa y métodos para fabricarlas y sus usos
CL2021000849A1 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos (divisional de la solicitud no. 201900999)
CO2019012475A2 (es) Composiciones y productos de fragancia novedosos con efectos mejoradores del estado de ánimo
PE20211225A1 (es) Constructos de arni para inhibir la expresion de pnpla3
ECSP21088111A (es) Analogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
UY38701A (es) Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
EA202092695A1 (ru) Композиции, содержащие глюкозу и гемицеллюлозу, и их применение
CO2022018636A2 (es) Moduladores de il-17a
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
CO2022006708A2 (es) Anticuerpos trem2 y usos de estos
DOP2024000020A (es) Anticuerpos contra el receptor alfa de la interleucina-4 humana
ECSP23087684A (es) Compuestos y métodos dirigidos a la epirregulina
CL2023001565A1 (es) Inhibidores de enzimas